NCT03825380View on ClinicalTrials.gov

Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients

PHASE3CompletedINTERVENTIONAL

Enrollment

485

Participants

Timeline

Start Date

November 23, 2018

Primary Completion Date

February 3, 2021

Study Completion Date

February 24, 2021

Conditions

Ocular HypertensionGlaucoma

Interventions

DRUG

Bimatoprost

Eyedrops

DRUG

Lumigan®

Eyedrops

Trial Locations (1)

Unknown

Hospital, Tallinn

Sponsors

Lead Sponsor

Laboratoires Thea

All Listed Sponsors

lead

Laboratoires Thea

INDUSTRY